142 related articles for article (PubMed ID: 15756584)
1. Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies.
Girmenia C; Cimino G; Di Cristofano F; Micozzi A; Gentile G; Martino P
Support Care Cancer; 2005 Dec; 13(12):987-92. PubMed ID: 15756584
[TBL] [Abstract][Full Text] [Related]
2. Must we really fear toxicity of conventional amphotericin B in oncological patients?
Mayer J; Doubek M; Vorlìcek J
Support Care Cancer; 1999 Jan; 7(1):51-5. PubMed ID: 9926976
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
4. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
5. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
6. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G
Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521
[TBL] [Abstract][Full Text] [Related]
7. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study.
Mayer J; Doubek M; Doubek J; Horký D; Scheer P; Stepánek M
J Infect Dis; 2002 Aug; 186(3):379-88. PubMed ID: 12134234
[TBL] [Abstract][Full Text] [Related]
8. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC.
Uehara RP; Sá VH; Koshimura ET; Prudente FV; Tucunduva LT; Gonçalves MS; Samano ES; del Giglio A
Sao Paulo Med J; 2005 Sep; 123(5):219-22. PubMed ID: 16358096
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
Imhof A; Walter RB; Schaffner A
Clin Infect Dis; 2003 Apr; 36(8):943-51. PubMed ID: 12684904
[TBL] [Abstract][Full Text] [Related]
11. Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants.
Holler B; Omar SA; Farid MD; Patterson MJ
Pediatrics; 2004 Jun; 113(6):e608-16. PubMed ID: 15173544
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia.
Noguchi S; Takahashi N; Ito M; Teshima K; Yamashita T; Michishita Y; Ohyagi H; Shida S; Nagao T; Fujishima M; Ikeda S; Ito I; Fujishima N; Kameoka Y; Saitoh H; Tagawa H; Hirokawa M; Sawada K
Int J Clin Oncol; 2013 Dec; 18(6):983-7. PubMed ID: 23076821
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.
Stanzani M; Vianelli N; Cavo M; Maritati A; Morotti M; Lewis RE
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28607011
[TBL] [Abstract][Full Text] [Related]
14. Conventional Amphotericin B Associated Nephrotoxicity in Patients With Hematologic Malignancies.
Gursoy V; Ozkalemkas F; Ozkocaman V; Serenli Yegen Z; Ethem Pinar I; Ener B; Akalın H; Kazak E; Ali R; Ersoy A
Cureus; 2021 Jul; 13(7):e16445. PubMed ID: 34422476
[TBL] [Abstract][Full Text] [Related]
15. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules.
Bernardo JF; Murakami S; Branch RA; Sabra R
Nephron; 1995; 70(2):235-41. PubMed ID: 7566310
[TBL] [Abstract][Full Text] [Related]
16. [Retrospective investigation on the cases treated with liposomal amphotericin B].
Yamagishi Y; Mikamo H
Jpn J Antibiot; 2010 Oct; 63(5):347-64. PubMed ID: 21268407
[TBL] [Abstract][Full Text] [Related]
17. Neonatal fluid and electrolytes profile effect on amphotericin B associated nephrotoxicity in neonatal tertiary care unit of Karachi-Pakistan.
Ambreen G; Rehman A; Hussain K; Sohail M; Javed S; Shamim S; Ali U; Ahmad K; Rizvi A
Expert Opin Drug Saf; 2020 Sep; 19(9):1209-1217. PubMed ID: 32544349
[TBL] [Abstract][Full Text] [Related]
18. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
19. Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study.
Okada N; Azuma M; Imanishi M; Zamami Y; Kirino Y; Nakamura T; Teraoka K; Abe M; Ishizawa K
Clin Ther; 2018 Feb; 40(2):252-260. PubMed ID: 29305017
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
Dutta A; Palazzi DL
Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
